Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BAY-293 + Osimertinib + RMC-4550|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BAY-293||BAY293|BAY 293||BAY-293 inhibits the interaction between Kras and Sos1, leading to reduced Erk phosphorylation, and potentially leading to decreased cell proliferation (PMID: 30683722).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 21||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EFGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EFGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|RMC-4550||SHP2 Inhibitor 14||RMC-4550 is a small molecule allosteric inhibitor of Shp2 that blocks Ras-Raf-Mek-Erk pathway signaling, leading to tumor growth inhibition (PMID: 30104724).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|